AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best multibagger penny stocks to invest in. On March 27, Deutsche Bank initiated ...

AtaiBeckley is well-capitalized with $220.7M in cash, sufficient to fund operations into 2029 and progress multiple TRD and ...

Day 2 following a single intranasal dose of BPL-003 in both the 10 mg (n=6) and 12 mg (n=6) cohorts; Durable responses ...

View AtaiBeckley Inc. ATAI stock quote prices, financial information, real-time forecasts, and company news from CNN.

Atai Life Sciences (NASDAQ: ATAI), a biotech focused on developing psychedelic-based medicines to treat mental health disorders, was a standout stock over the past few days in its rather limited peer ...

Why AtaiBeckley (ATAI) is on investors’ radar today AtaiBeckley (ATAI) has attracted fresh attention after a period of mixed ...

Shares in key competitors COMPASS Pathways and MindMed have shown signs of recovery but Atai shares have remained unchanged. Major news items, such as FDA approval for MDMA-Assisted therapy and phase ...

In its 2022 Q4 report, Atai reiterated that it is well capitalized, with a cash runway into the first half of 2026. Its sound financial position and deep clinical pipeline appear to have sparked a ...

Loop Capital initiated coverage of the stock with a buy rating. atai has several therapies in late-stage trials but no marketed drugs yet. The company said it has enough cash to fund operations ...

Invyxis will add proven medicinal chemistry and comprehensive biological evaluation capabilities to grow atai’s portfolio of new chemical entities (NCEs) Early focus will be on designing unique, novel ...

atai's mission is to tackle the significant unmet needs and lack of innovation in the treatment landscape by working with psychedelic and non-psychedelic compounds. atai is one of the leading ...